Opinion|Videos|December 18, 2024

Case 3: Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence

Key Takeaways

Panelists discuss how the management of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence involves careful monitoring and the potential use of novel therapies, such as androgen receptor inhibitors, to delay progression and improve patient outcomes.